<SEC-DOCUMENT>0001493152-24-011937.txt : 20240329
<SEC-HEADER>0001493152-24-011937.hdr.sgml : 20240329
<ACCEPTANCE-DATETIME>20240329143030
ACCESSION NUMBER:		0001493152-24-011937
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240329
FILED AS OF DATE:		20240329
DATE AS OF CHANGE:		20240329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		24803690

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 29, 2024, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing, its interim results for the six months
ended 30 September 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 29, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Results, dated March 29, 2024</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 69.75pt; width: 184.5pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">London
and New York, NY, March 29, 2024 &ndash; OKYO Pharma Limited (NASDAQ: OKYO), <FONT STYLE="color: #1A1A1A; background-color: white">a
clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED),
a multi-billion-dollar market, and for neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved
therapy,</FONT> today announces its interim results for the six months ended 30 September 2023.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Clinical
Updates:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the past six months the Group&rsquo;s primary focus has been centered on completing the Phase 2 trial of OK-101 to treat DED and on analyzing
its results, as well as advancing OK-101 towards a corneal neuropathic pain indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
and post this period, the Group accomplished the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            the Phase 2 trial of OK-101 in 240 dry eye disease patients according to projected timelines</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reported
                                            positive top line data for the Phase 2 DED trial in January 2024</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Received
                                            IND clearance from the U.S. Food and Drug Administration (FDA) to test OK-101 in patients
                                            with neuropathic corneal pain.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Reported
                                            positive new findings from its Phase 2 trial of OK-101 in dry eye disease patients including
                                            a statistically significant and durable reduction in ocular pain and a statistically significant
                                            improvement in Tear Film Break-Up Time (TFBUT) throughout the study in patients receiving
                                            the 0.05% dose of OK-101. Multiple symptomatic improvements were also observed by during
                                            patient clinic visits as well as collected from patient daily symptom diaries for patients
                                            receiving the 0.05% dose.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 74pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
OK-101 first-in-human Phase 2 trial established a clear clinical path for further clinical development in a Phase 3 study design using
FDA recognized endpoints. OK-101 demonstrated statistically significant benefit in the sign endpoint of total conjunctival staining as
measured by the Ora Calibra<SUP>&copy;</SUP> Staining Scale as early as Day 29 (p = 0.034). OK-101 also improved at least two symptoms
of DED including burning measured by the Ora Calibra<SUP>&copy;</SUP> 4-symptom questionnaire as well as burning/stinging measured by
a visual analogue scale as early as Day 15 (p = 0.04 and p=0.03, respectively). A statistically significant improvement in blurred vision
was also achieved at Day 29 (p = 0.01).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
analyses also showed statistically significant improvement in ocular pain measured by VAS that was durable throughout the trial with
p values = 0.03, 0.04 and 0.01 at Days 29, 57 and 85, respectively. Furthermore, OK-101 improved TFBUT as early as Day 15 and the improvement
lasted throughout the trial with p values = 0.01, 0.05, 0.02, and 0.03 at Days 15, 29, 57 and 85, respectively. Additionally, data obtained
from daily symptom diaries maintained by patients during the trial, commonly referred to as patient-reported outcome data, confirmed
several of the DED symptoms also measured in the clinic, exhibiting significant improvements as early as Day 1 through Day 15 for pain,
burning/stinging, eye dryness and itching, with p values of 0.01, 0.06, 0.005 and 0.009, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Treatment
emergent adverse events (TEAEs) were observed to be similar to the placebo-treated group. No severe drug related ocular TEAEs were seen.
Possible drug-related TEAEs were observed in one patient in the OK-101 0.05% treatment group and 3 patients in the placebo-treated group,
again highlighting the favourable safety profile of OK-101.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">OKYO
plans to engage with the FDA on next steps forward with an End-of-Phase 2 meeting with the Agency, and is planning to begin the Phase
3 trial of OK-101 in DED by the end of 2024..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">In
February 2024, the Company announced that it was the first company that had received Investigational New Drug Application (IND) clearance
to study OK-101 in neuropathic corneal pain (NCP). The Company plans to initiate a Phase 2 trial in NCP in 2024.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; background-color: white">The
Phase 2 study is designed as a double-masked, randomized, 12-week placebo-controlled trial comparing OK-101 to placebo in NCP patients.
A total of 54 patients are planned for the study, with NCP disease confirmed <I>via</I> confocal microscopy. The primary endpoint will
be measured utilizing VAS pain relief scores. The OK-101 trial, designed as a single-center trial, will be led by Pedram Hamrah, MD,
of Tufts Medical Center, as Principal Investigator. Dr. Hamrah is Professor and Vice Chair of Research and Academic Programs, Co-Director
of the Cornea Service and Director of the Center for Translational Ocular Immunology at Tufts Medical Center.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; color: #1A1A1A; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Highlights:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Total
                                            assets of &pound;1.9 million (31 March 2023: &pound;4.2 million)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Cash
                                            on hand of &pound;1.3 million (31 March 2023: &pound;3.3 million)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">During
                                            the financial period under review, the Company reported a total comprehensive loss of &pound;7.0million
                                            (compared to total comprehensive loss of &pound;4.6 million for the six months ending September
                                            30 2022)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">OKYO&rsquo;s
interim results can be accessed by visiting the investors section of the company&rsquo;s website at <U>https://okyopharma.com/investors/corporate-governance/corporate-documents</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1A1A1A">OKYO
Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED
and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel
molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway
for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please
visit </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>www.okyopharma.com<FONT STYLE="color: #1A1A1A">.</FONT></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enquiries:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
    Pharma Limited</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    S. Jacob, Chief Executive Officer</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">917-497-7560</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
    Development &amp; Investor Relations</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Spencer</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
    (0)20 7495 2379</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #7 CH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@@D5H5\:?3!117,_&+XQ?#+X ?#/6/C%\9/&MCX=\,Z!9M=:MK&HR[8K>,$
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MAI5W*V/E(GEN+J->>H\DY]J_*2BIED^6RC9TE^7Y#CF..B[JH_S/Z6OV!_\
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MD5RRC+FL]6?MV4YEEM?)XXNA'V6'M>/,E!<BVE;[,6M5>VFMCD>37L'[//[
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M$FGF?3@SXV@7D&^W8G(&!(>>.O%>5*ZO]WZ]*_K/,<;##1K_ -\U\K_M0_\
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MV4ZBJ1/Y@XPX2QG">9>QJ>]2E=PGW79]I+JO1K1ERBBBM#Y$**** "OYJO\
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MV?\ \:KNJ*_.G4J2=VW]Y]M[.FMDCA?^&7_V:O\ HWOP/_X2=G_\:H_X9?\
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ME%MGEU]M_P#!.+_@@M\*/V>6L_BU^U>FF^.?&BYDM-%\OSM&TEN0I"2*#=S
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M]!7_  3/_P""=7@#]@#X*P^'X8;/4O&FL0QS>,/$D2'-Q-U$$18 K;QDE5&
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M\ ?&7P+J7PT^*/A*QUW0=6MS!J&EZC")(IER",@]&# ,K AE9592" 1^)?\
MP5-_X(L^/?V1+O4/V@/V;5OM<^&\<C75U9QLTFH>&>K$N1S+;)C(G^\@XD^[
MYK\;IRHRYH['[EE?%^4\?Y8\ESI*G6E\$U\+DMFOY9>5[23:35^4_=('/-%?
M&?\ P1F_X*,1?MO_  #'A/XA:M&WQ&\&PQ6_B3?\K:G;D$0Z@HP 2^TK(%^[
M(I.$62,5]F5TQDI1NC\2S;*\9DN8U,%B5:<'9]GV:\FK-/LPHHHIGG!7\O?_
M  <4?\IB/BY_N^'_ /TP:=7]0E?R]_\ !Q1_RF(^+G^[X?\ _3!IU?2<+_\
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M6KX)MA=>%_A7H,^WP[X-2;;)=,@V"]ORI(EN",D("8X =B;FWS2_'-?T)?\
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MSR2%GD=BSLS$D_QL:;J6I:-J=MK6C:C<6=Y9W"3VEU:S&.2&5&#)(C#!5E8
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M (4KKEZX\.^.)/*AB=ODMM3"_N9!SQY@!A( RS&+/"U^H"MN4-ZU^(WQ$O\
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M:1_\LZ^#>3YFM/9,^L_M+ _\_$?J117Y;_\ $6C_ ,$\O^B)?&C_ ,$&D?\
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MR*_LR^+GP,^"_P ??"[>"?CC\)?#?C#1S+YJZ9XGT2"^@60 @2!)E95<9.&
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MQC?WUKI'C3PS?:'JEUI<B)<Q6]U \$C1-(CJKA7)4LK '&01Q7YSK_P:7?\
M!.H#'_"ZOC5_X46D?_*NOI<CS3"X"C.-6^KOHKGAYME^(QE6,J=M%8_%/_@F
MG_RD9^ /_9:O"W_IVMJ_KP'2OSC^"'_!L1^P=\ _C1X1^.G@WXO?%ZXUCP7X
MGL-=TJWU+7M+>WDN;2X2XC654TU6:,O&H8*RDC."#S7Z.*"% -<V>9AA\PK0
ME2OHNJ-LIP=;!TY*IU84445X9ZP5Y+^W'^R'\//VZ?V8/%7[,OQ*+06?B&S
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M1+?XK_ #XDZAX:UN&,Q-<V,@*7$)()AFB8&.>(LJDQR*RY53C*@C]FOV!O\
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M_8Y^()\#_$FT:2SF9SHFO01-]EU.(8^9"?NNH(WQD[D)'565F_9:L7Q[\//
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M1S;,H^VFO94MW.>BMW2>K]=%YGT.9<3Y;@)>R@_:5-E&.KOV;V7IJ_(_1O\
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M+9WEC)X6N+:-Y7EF=&63SX)00 HQ@ Y[U^D7_$)-^P7_ -' ?%[_ ,&6E_\
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MGRO#U,/+%8OX%MJUZO3[EYGAYECZT*RP^'^+KU^7ZL_H5_X)1_\ !8CX(?\
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M7P5UE[O0?$=GYT,=Q&$GM)5)66VF4$A98I T; %ERN59E*L?1J_F1_X(3_\
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MBNU9=/GZGS.-S>I]94*#T3U>]_\ @']F (/2BD0808%+7QI],%</^TC^T/\
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M_P!VOY"/^"B W?\ !0KX[+Z_&;Q/_P"G:YK^O=_NU_(1_P %#O\ E(9\=/\
MLLWB;_T[7-;\+?[Q4]/U,\^_@P]3ZS_X. _^"1\G["_QB;]H_P"">CQK\)_'
M6J-Y>GV<&Q?"^J,I=K+:./L\F))(",!0'AVJ(XVD^I?^#:G_ (*\-K5G8_\
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M#:S\1_'FO0:7HN@:3<:EJ^I76?+M;6"-I)96Q_"J*S'O@5\"M=$?7;+4^/\
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MX7&I^"=<=OFU'2)7;[/,2%7]ZFUH9,*%$T,FW*A6/L7]K_\ !QY_SS_;,_\
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M,JRD<$&OL"BM,3FE3$X&&%<4E&VOHFOU,Z&7PH8N>(4FW*^GJT_T/"_VXO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
